Diminished quality of life in patients with cancer correlates with tryptophan degradation
- 14 March 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 133 (7), 477-485
- https://doi.org/10.1007/s00432-007-0191-3
Abstract
Quality of life (QoL) is frequently impaired in patients suffering from malignant disease. Disturbed metabolism of neurotransmitter serotonin might be crucially involved, and serotonin-precursor tryptophan is degraded during pro-inflammatory immune response. In this study, we compared QoL and fatigue self-rating scores of patients with various types of malignancy with tryptophan metabolic changes and immune activation status.Keywords
This publication has 41 references indexed in Scilit:
- Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan MetaboliteScience, 2005
- Tryptophan degradation in patients with gynecological cancer correlates with immune activationCancer Letters, 2005
- Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatmentAnnals Of Oncology, 2004
- Neopterin production, tryptophan degradation, and mental depression—What is the link?Brain, Behavior, and Immunity, 2002
- Immune reaction links disease progression in cancer patients with depressionMedical Hypotheses, 2000
- Molecular Basis of Sickness BehavioraAnnals of the New York Academy of Sciences, 1998
- Decreased Serum Tryptophan in Patients with Cancer Cachexia Correlates with Increased Serum NeopterinImmunological Investigations, 1995
- Predictive Value of Urinary Neopterin in Patients with Lung Cancercclm, 1995
- Correlation between neopterin, interferon‐gamma and haemoglobin in patients with haematological disordersEuropean Journal of Haematology, 1990
- Interferons and indoleamine 2,3-dioxygenase: Role in antimicrobial and antitumor effectsCellular and Molecular Life Sciences, 1989